Opinion
Video
Author(s):
Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.
Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL
Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
NX-5948 Demonstrates Preliminary Efficacy in High-Risk CLL
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
Zanubrutinib Plus Obinutuzumab/Venetoclax Associated With Durable uMRD4 Outcomes in Treatment-Naive CLL
Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma
Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma
Obe-Cel Represents a Unique CAR T-Cell Therapy for Patients with Relapsed/Refractory ALL
Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field
Short-Course Radiation Therapy Effective for Endometrial Cancer Patients
NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines